Eline van der Burg

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen et al. · Proceedings of the National Academy of Sciences · 2008 · 949 citations · Full text

Medicine, Oncology, Pharmacology +16

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

Bastiaan Evers, Rinske Drost, Eva Schut et al. · Clinical Cancer Research · 2008 · 334 citations · Full text

Medicine, Oncology, Pharmacology +16

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

Petra ter Brugge, Petra Kristel, Eline van der Burg et al. · JNCI Journal of the National Cancer Institute · 2016 · 208 citations

Medicine, Oncology, Pharmacology +16

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

Rinske Drost, Kiranjit K. Dhillon, Hanneke van der Gulden et al. · Journal of Clinical Investigation · 2016 · 141 citations · Full text

Life Sciences, Genetics, Oncology +16

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

Dario Zimmerli, Chiara Svetlana Brambillasca, Francien Talens et al. · Nature Communications · 2022 · 137 citations · Full text

Medicine, Immunology, Oncology +17